The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Advancements in immunotherapy for metastatic colorectal cancer
Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, comments on the standard use of immunotherapies in the treatment of metastatic colorectal cancer, with pembrolizumab being a long-standing option. However, the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) may offer improved outcomes. The CheckMate 8HW (NCT04008030) trial will provide more insight into the effects of nivolumab and ipilimumab when used separately, and further randomized data will help determine whether monotherapy or combinatorial therapy is more effective. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
